Acadian Asset Management
AXDX

Acadian Asset Management’s Accelerate Diagnostics AXDX Stock Holding History

Acadian Asset Management’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-8,129
Closed -$57K – 1744
2022
Q4 		$57K Buy
+8,129
New +$88.7K ﹤0.01% 1556
2022
Q3 		– Sell
-3,823
Closed -$38K – 1669
2022
Q2 		$38K Buy
+3,823
New +$33.8K ﹤0.01% 1541

Other funds holding AXDX

GAM
Griffin Asset Management New York $887M AUM 21.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return

Acadian Asset Management's AXDX Position: Q1 2023 in Review

Acadian Asset Management sold out of Accelerate Diagnostics (AXDX) in Q1 2023, closing a stake of 8,129 shares — an estimated $57K sold.

Acadian Asset Management first reported a position in AXDX in Q2 2022 and held it in 2 quarters. The position peaked at $57K in Q4 2022. 66 funds tracked by Wall St. Rank hold AXDX as of Q1 2023.

  • Acadian Asset Management reported no remaining Accelerate Diagnostics position as of Q1 2023 after selling out during the quarter.
  • Acadian Asset Management sold 8,129 Accelerate Diagnostics shares in Q1 2023, an estimated $57K.
  • Acadian Asset Management first reported a position in Accelerate Diagnostics in Q2 2022 and held it in 2 quarters.
  • Acadian Asset Management's Accelerate Diagnostics position peaked at $57K in Q4 2022.
  • 66 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2023.

Based on Acadian Asset Management's 13F filing for Q1 2023, filed 11 May 2023.